Rejected at 9:50 p.m. Oct, 31, 2023 ] by dollajas
Author: northo
Related Note: 1501987087158
Rationale for change

CDC guidelines were updated over the past couple years, doxy is now preferred over azithro given evidence of superior efficacy

Rejection reason

i don't like making decisions based off of CDC guidance alone - since that has never correlated strongly with practice questions. also this source seems to indicate that the treatment regimen would be more complicated depending on route of transmission and sex of the individual... resubmit if you see a uworld or amboss change to this effect please.

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step3_v12::#UWorld::5478 #AK_Step1_v12::#UWorld::Step::6814 #AK_Step2_v12::#SketchyOBGYN::05_Benign_Gynecology_&_Urogynecology::01_STIs_&_Other_GYN_Infections::02_Cervicitis_&_PID_SOAPs #AK_Step1_v12::#FirstAid::03_Microbiology::06_Systems::12_Sexually_transmitted_infections #AK_Step2_v12::#NBME::Form09 #AK_Step1_v12::#UWorld::Step::6781 #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::14_Macrolides #AK_Step2_v12::#AMBOSS::830O4f #PANCE::EOR::Family_med #PANCE::GU::urethral_disorders #AK_Step2_v12::#AMBOSS::AXaR0j #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step3_v12::#UWorld::12585 #AK_Other::Only_Step_1&2_Overlap #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Bugs #AK_Step1_v12::#Pixorize::04_Microbiology::05_Bacteria-Gram_Negative::28_Chlamydia_trachomatis #AK_Step1_v12::#Bootcamp::Microbiology::16_Atypical_Bacteria::02_Chlamydia_Trachomatis_Serotypes_and_Disease_Variants #AK_Step2_v12::#B&B::09_MSK::01_General::02_Arthritis_II::Extra #AK_Step1_v12::#Physeo::06_Micro::02_Bacteria::47_Chlamydia_Trachomatis,_Chlamydophila_Pneymoniae_&_Chlamydophila_Psittaci #AK_Step1_v12::#UWorld::COMLEX::25257 #AK_Step1_v12::#Bootcamp::Microbiology::16_Atypical_Bacteria::03_Chlamydia_Pneumoniae_and_Psittaci #AK_Step2_v12::#SketchyIM::09_Infectious_Diseases::03_GU_Infections::03_Urethritis_in_Males #AK_Step1_v12::#SketchyMicro::01_Bacteria::10_Gram-indeterminate_Bacteria::01_Chlamydia_trachomatis,_Chlamydophila_pneumoniae_&_Chlamydophila_psittaci #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::02_Inhibitors_of_Bacterial_Protein_Synthesis::02_Macrolides #AK_Step2_v12::#B&B::08_Infectious_Disease::04_Other::02_Sexually-transmitted_Infections #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::13_Tetracyclines_and_Derivatives #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Infectious_Disease #AK_Step2_v12::#SketchyIM::09_Infectious_Diseases::02_Lung_Infections::02_Pneumonia_Management #AK_Step2_v12::#B&B::11_Obstetrics_and_Gynecology::01_Obstetrics::07_Perinatal_Infections::Extra #AK_Step1_v12::#B&B::14_Infectious_Disease::02_Bacteria::05_Other_Gram_Negatives #AK_Step1_v12::#FirstAid::03_Microbiology::02_Clinical_Bacteriology::44_Chlamydiae